Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Equity Ratio (2022 - 2025)

Historic Equity Ratio for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to 0.83.

  • Entrada Therapeutics' Equity Ratio rose 833.02% to 0.83 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.83, marking a year-over-year increase of 833.02%. This contributed to the annual value of 0.81 for FY2024, which is 5767.77% up from last year.
  • Per Entrada Therapeutics' latest filing, its Equity Ratio stood at 0.83 for Q3 2025, which was up 833.02% from 0.85 recorded in Q2 2025.
  • Entrada Therapeutics' Equity Ratio's 5-year high stood at 0.88 during Q1 2022, with a 5-year trough of 0.42 in Q2 2023.
  • Its 4-year average for Equity Ratio is 0.72, with a median of 0.81 in 2024.
  • Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 5159.07% in 2023, then skyrocketed by 7637.3% in 2024.
  • Over the past 4 years, Entrada Therapeutics' Equity Ratio (Quarter) stood at 0.84 in 2022, then crashed by 38.75% to 0.52 in 2023, then skyrocketed by 57.68% to 0.81 in 2024, then increased by 1.31% to 0.83 in 2025.
  • Its last three reported values are 0.83 in Q3 2025, 0.85 for Q2 2025, and 0.86 during Q1 2025.